In a first-in-human clinical trial for patients with relapsed multiple myeloma, led by researchers at Indiana University Melvin and Bren Simon Comprehensive Cancer Center, patients treated with higher doses of the immunotherapy called REGN5459 resulted in a 90.5% overall response rate.
Zhan, seated, with Steven Webber (left), dean of the College of Medicine and executive vice chancellor at UAMS, and UAMS chancellor Cam Patterson (right).The University of Arkansas for Medical Sciences College of Medicine invested Fenghuang “Frank” Zhan, a tenured professor of medicine and the research director of the UAMS Winthrop P. Rockefeller Cancer Institute’s Myeloma Center, in the Bart Barlogie Chair for Myeloma Research during a March 13 ceremony.
